Denmark’s Xellia hiring at Ohio plant, hopes to begin manufacturing next year

Xellia looks to begin sterile injection production at Ohio plant in 2018.

Xellia Pharmaceuticals, the maker of anti-infective treatments, is hiring at the former Ben Venue Labs in Bedford, Ohio, as it prepares to begin drug manufacturing at the site next year.

The facility, at which the Copenhagen-based company received FDA approval in 2016 for packaging and distribution operations, still needs approval from the regulatory agency to begin sterile injectable drug production.

A spokesman for the company, Niels Lynge Agerbaek, told cleveland.com that the facility is on track to receive the approval in 2018. Currently, most of the products packaged and distributed from the Bedford site come from the company's European facilities.

"A huge amount of renovation has been going on,” Agerbaek told the news site. “We're operating with upgraded equipment and we're getting all the paperwork together to make sure we are in compliance to pass inspection.”

The company is looking to fill about 70 positions for mechanics and operators right now, but is expected to broaden the hiring in the coming months for engineering, quality assurance and supply-chain jobs. So far, Xellia has hired about 130 people to work in its laboratories and warehouse and distribution center.